Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

AI in Clinical Trials Doesn't Have a Capability Problem. It Has a Honesty Problem.

8 September 2026 · By · Wire by Fusion42

Published

8 September 2026

Topic

opportunities

◆ Sectors

BiotechAI InfrastructureDigital Health

◆ Geography

United States

◆ Source

Read at clinicaltrialvanguard.com →

◆ Verified

Fusion42 · 8 September 2026 · Fusion42 review

The article argues that AI in clinical trials is limited not by technical capability but by overreliance on patterns from past data and insufficient human judgement, which risks automation bias in high-volume approval workflows.

This Wire brief sits within Fusion42's coverage of Biotech, AI Infrastructure and Digital Health.

◆ ◆ The Wire takeaway

You face rising risks from human review that blindly approves AI outputs without real oversight. Challenge your workflow now to avoid automation bias turning your oversight into a costly formality.

◆ Coverage

1 source · 8 Sep 2026

◆ Related on Wire

◆ Topics

BiotechAI InfrastructureDigital Healthclinical-trialsai-governanceautomation-biashealthtechpatient-safety